Efecto del uso de agua residual tratada sobre el suelo y cultivos forrajeros de Chenopodium quinoa Willd y Zea mays L.

Given the scarcity of water resources for agricultural use, it is necessary to promote the use of wastewater for agriculture. The towns of Capulálpam de Méndez and Ixtlán de Juárez in the State of Oaxaca have anaerobic wastewater treatment plants (WWTP). The morphological growth, biomass production and N and P content were evaluated in two forage species —Chenopodium quinoa Willd and Zea mays— irrigated with treated wastewater (TWW). A complete randomized design (CRD) was established in each municipality, given the homogeneity of the soil, using a 2 x 2 factorial arrangement, i.e., two forage crops (Quinoa and corn) and two types of irrigation (fresh water and treated wastewater), with 4 replicates per treatment. Analyses of variance and Tukey mean tests (P≤0.05) were performed for the studied variables. In the soils, the pH level was "moderately acid" to "neutral" (5.1 to 7.3); the EC indicated "negligible effects of salinity"; organic matter was found at intervals of "medium to high", and the texture was sandy clay loam in Ixtlán and clay loam in Capulálpam. Growth variables (plant height, stem diameter, and number of leaves) and biomass were significantly higher in plants irrigated with treated wastewater in both forage crops. Nitrogen and phosphorus contents were significantly higher in quinoa and corn plants receiving TWW. TWW could be an alternative that would help reduce the use of chemical fertilizers, as it is an important source of nutrients in forage crops.Ante la escasez del recurso hídrico para el uso agrícola, es necesario promover el uso del agua residual para la agricultura. En las localidades Capulálpam de Méndez e Ixtlán de Juárez, Estado de Oaxaca cuentan con plantas de tratamiento de aguas residuales (PTAR) de tipo anaerobio. Se evaluó el crecimiento morfológico, producción de biomasa y contenido de N y P en dos especies forrajeras: Chenopodium quinoa Willd y Zea mays, regados con agua residual tratada (ART). Se estableció un diseño completo aleatorio (DCA) en cada municipio, dada la homogeneidad del suelo. Con arreglo factorial 2 x 2, esto es, dos cultivos forrajeros (Quinoa y maíz), y dos tipos de riego (agua dulce y agua residual tratada), con 4 repeticiones por tratamiento. Se realizaron análisis de varianza y pruebas de media Tukey (P≤0.05) de las variables estudiadas. En los suelos el nivel de pH fue “moderadamente acido” a “neutro” (5.1 a 7.3); la CE indicó “Efectos despreciables de la salinidad”; Materia orgánica en intervalos de “medio a alto”; y Textura Franco arcilloso arenoso en Ixtlán y Franco arcilloso en Capulálpam. Las variables de crecimiento (altura de planta, diámetro de tallo y número de hojas) y biomasa fueron significativamente mayores en plantas regadas con agua residual tratada en ambos cultivos forrajeros. El contenido de nitrógeno y fósforo fue significativamente mayor en plantas de quinoa y maíz que recibieron ART. El ART podría ser una alternativa que ayude a disminuir el uso de fertilizantes químicos, al ser una fuente importante de nutrimentos en los cultivos forrajeros

Conocimiento tradicional y contenido nutricional de Salmea scandens

Salmea scandens, conocida como palo de chile, es una planta económicamente importante en la región costa de Oaxaca. Con el objetivo de documentar el conocimiento tradicional de su uso y el contenido de nutrientes de la parte comestible, se realizó un estudio en Buena Vista Loxicha, Pochutla, Oaxaca, por medio de entrevistas semiestructuradas. Se recolectaron muestras de tallo para cuatificar el contenido de fibra cruda, grasa, proteína y minerales. Se encontraron dos morfotipos: palo de chile blanco y palo de chile negro, con usos comestible y medicinal. De las plantas se consume el cámbium vascular del tallo, preferentemente hervido, que contiene 9.44% de fibra cruda, 2.51% de grasa y 3.10% de proteína. El mineral más abundante fue el potasio con 505.53 mg 100 g-1

Reconstructing Native American Population History

The peopling of the Americas has been the subject of extensive genetic, archaeological and linguistic research; however, central questions remain unresolved1–5. One contentious issue is whether the settlement occurred via a single6–8 or multiple streams of migration from Siberia9–15. The pattern of dispersals within the Americas is also poorly understood. To address these questions at higher resolution than was previously possible, we assembled data from 52 Native American and 17 Siberian groups genotyped at 364,470 single nucleotide polymorphisms. We show that Native Americans descend from at least three streams of Asian gene flow. Most descend entirely from a single ancestral population that we call “First American”. However, speakers of Eskimo-Aleut languages from the Arctic inherit almost half their ancestry from a second stream of Asian gene flow, and the Na-Dene-speaking Chipewyan from Canada inherit roughly one-tenth of their ancestry from a third stream. We show that the initial peopling followed a southward expansion facilitated by the coast, with sequential population splits and little gene flow after divergence, especially in South America. A major exception is in Chibchan-speakers on both sides of the Panama Isthmus, who have ancestry from both North and South America

CIBERER : Spanish national network for research on rare diseases: A highly productive collaborative initiative

Altres ajuts: Instituto de Salud Carlos III (ISCIII); Ministerio de Ciencia e Innovación.CIBER (Center for Biomedical Network Research; Centro de Investigación Biomédica En Red) is a public national consortium created in 2006 under the umbrella of the Spanish National Institute of Health Carlos III (ISCIII). This innovative research structure comprises 11 different specific areas dedicated to the main public health priorities in the National Health System. CIBERER, the thematic area of CIBER focused on rare diseases (RDs) currently consists of 75 research groups belonging to universities, research centers, and hospitals of the entire country. CIBERER's mission is to be a center prioritizing and favoring collaboration and cooperation between biomedical and clinical research groups, with special emphasis on the aspects of genetic, molecular, biochemical, and cellular research of RDs. This research is the basis for providing new tools for the diagnosis and therapy of low-prevalence diseases, in line with the International Rare Diseases Research Consortium (IRDiRC) objectives, thus favoring translational research between the scientific environment of the laboratory and the clinical setting of health centers. In this article, we intend to review CIBERER's 15-year journey and summarize the main results obtained in terms of internationalization, scientific production, contributions toward the discovery of new therapies and novel genes associated to diseases, cooperation with patients' associations and many other topics related to RD research

¿Qué queda de mí?

Este libro es una reclamación a quienes hemos sido, somos o seremos docentes. A quienes no hemos respetado a las personas que se han puesto junto a nosotros y nosotras, confiando su bien más preciado: la libertad. Estas páginas denuncian cada vez que convertimos una visión en la visión, una emoción en la emoción, un saber en el saber, un comportamiento en el comportamiento. Es un grito contra la imposición, la normalización, la neutralización y la universalización de una perspectiva particular. Una pugna contra cada proceso que no se ha conectado con las vidas de los aprendices. Un texto colaborativo realizado por alumnado de Educación y Cambio Social en el Grado en Educación Infantil de la Universidad de Málaga y coordinado por Ignacio Calderón Almendros

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline